On June 15, 2018, Health Canada announced the publication of proposed Regulations Amending the Food and Drug Regulations (Serious Adverse Drug Reaction Reporting — Hospitals) and the Regulations Amending the Medical Devices Regulations (Medical Device Incident Reporting — Hospitals). The regulations specify that for the purposes of section 21.8 of the Food and Drugs Act, as amended by Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law), hospitals are the prescribed health care institutions that shall provide information in their control to the Minister of Health. Pursuant to the proposed amendments, all hospitals must provide the specified information relating to serious adverse drug reactions and medical device incidents (as defined in the proposed amendments) directly to Health Canada within 30 days of first documenting the reaction or incident in the hospital. The reporting requirements apply to pharmaceuticals (prescription and non-prescription), biologic drugs (excluding vaccines that are part of a routine immunization program), radiopharmaceuticals, disinfectants and medical devices, but exclude these products when used in clinical trials or as part of the Special Access Programme. The consultation period ends on August 30. We have updated our previously published chart (An Update on Vanessa’s Law) to include these proposed regulations.
Related Publications & Articles
-
Updates to Health Canada’s regulatory initiatives for 2022-2024, and amendments to Food and Drug Regulations (Exports and Transhipments of Drugs)
Health Canada has updated its Forward Regulatory Plan: 2022-2024, providing information on regulatory initiatives Health Canada aims to propose or finalize over the next two years.Read More -
Update on biosimilars in Canada – June 2022
We provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, market access and competition) since our last update in October 202...Read More -
Competition Bureau closes two investigations into pharmaceutical patent litigation settlements
On May 20, 2022, the Competition Bureau announced that it closed two investigations into pharmaceutical patent litigation settlement agreements as evidence gathered during the two investigations sugge...Read More